Electrophysiologic effects of lorcainide on the accessory pathway in the Wolff-Parkinson-White syndrome
- 1 June 1983
- journal article
- research article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 51 (10) , 1618-1622
- https://doi.org/10.1016/0002-9149(83)90197-2
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- Randomized double-blind placebo controlled crossover trial documenting oral lorcainide efficacy in suppression of symptomatic ventricular tachyarrhythmiasAmerican Heart Journal, 1982
- Electrophysiological effects of lorcainide in sinoatrial disease and in Wolff-Parkinson-White syndrome*European Heart Journal, 1982
- Electrophysiological effects of lorcainide, a new antiarrhythmic drug. Observations in patients with and without pre-excitation.Heart, 1981
- Resistant Ventricular Arrhythmias Treated with Lorcainide, a New Antiarrhythmic DrugChest, 1980
- Use of ajmaline in patients with the Wolff-Parkinson-White syndrome to disclose short refractory period of the accessory pathwayThe American Journal of Cardiology, 1980
- Lorcainide; II. Plasma concentration‐effect relationshipClinical Pharmacology & Therapeutics, 1979
- Lorcainide; I. Saturable presystemic eliminationClinical Pharmacology & Therapeutics, 1979
- Electrophysiological Actions of Lorcainide in Patients with Cardiac DiseaseJournal of Cardiovascular Pharmacology, 1979
- Intracardiac electrophysiological effects of lorcainide in manEuropean Journal of Clinical Pharmacology, 1979
- Initial clinical experience of lorcainide (Ro 13-1042), a new antiarrhythmic agentEuropean Journal of Clinical Pharmacology, 1978